nifedipine has been researched along with Stroke in 38 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects." | 9.12 | Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Vokó, Z, 2007) |
| "We examined the effect of a Ca antagonist (nilvadipine) on the occurrence or recurrence of symptomatic stroke in hypertensive patients with MRI-defined asymptomatic cerebral infarction (ACI), periventricular hyperintensity (PVH), and deep and subcortical white matter hyperintensity (DSWMH), with or without a history of stroke, and evaluated the effect of long-term treatment on the lesions." | 9.12 | Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment. ( Fukuuchi, Y; Hirai, S; Okudera, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2007) |
| "To examine the effects of nifedipine GITS on clinical outcome in patients with concurrent stable angina and hypertension." | 9.11 | Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Wagener, G, 2005) |
| "Use of short-acting nifedipine was associated with increased risk of stroke occurrence in elderly hypertensive patients." | 7.77 | Short-acting nifedipine and risk of stroke in elderly hypertensive patients. ( Chang, Y; Choi, NK; Jung, SY; Kim, JY; Lee, J; Park, BJ; Song, HJ, 2011) |
| " PAR(2) and bradykinin subtype 2 receptor (B(2)) expression and function were assessed in relation to hypertensive encephalopathy (HE) and cerebral hemorrhage (CH) in middle cerebral arteries (MCA) of Kyoto Wistar stroke-prone spontaneously hypertensive rats (SHRsp)." | 7.76 | Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats. ( Daneshtalab, N; McGuire, JJ; Smeda, JS, 2010) |
| " Benidipine treatment was associated with higher cardiovascular- and cardiac event-free rates than diltiazem treatment, and higher stroke- and ESRD-free rates than nifedipine." | 7.74 | Prognostic effects of calcium channel blockers on cardiac events, stroke and end-stage renal disease in patients with angina pectoris. Retrospective comparative study of benidipine, diltiazem and nifedipine. ( Arioka, I; Dohi, S; Sakai, K, 2008) |
| "A comparative study of pharmacodynamics and clinical efficacy of nimodipine, nifedipine and foridon in ischemic stroke (late recovery and residual period) was performed in 97 patients with ischemic stroke." | 7.71 | [Comparative clinico-pharmacological characteristics of nimodipine, nifedipine and foridon in the treatment of patients with ischemic stroke in late rehabilitative and residual periods]. ( Kurkova, KS; Svetyĭ, LI, 2002) |
| "Nifedipine and nimodipine, dihydropyridine calcium channel blockers, are commonly used as antihypertensive and antianginal agents in patients at risk for stroke." | 7.70 | Nifedipine and nimodipine competitively inhibit uridine kinase and orotidine-phosphate decarboxylase: theoretical relevance to poor outcome in stroke. ( Najarian, T; Traut, TW, 2000) |
| "Calcium antagonists are used in the treatment of hypertension and angina." | 6.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| " However, the short-acting formulations of nifedipine had pharmacokinetic properties that were far from ideal and in 1995, several studies involving various dosing regimens reported possible dangerous effects in secondary prevention." | 6.44 | Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension. ( Dunselman, PH; Kragten, JA, 2007) |
| "The increased efficacy on ambulatory BP as well as the significantly reduced prevalence of edema after bedtime as compared to morning ingestion of nifedipine should be taken into account when prescribing this medication to patients with essential hypertension." | 5.13 | Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. ( Ayala, DE; Fernández, JR; Hermida, RC; Mojón, A, 2008) |
| "The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects." | 5.12 | Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Vokó, Z, 2007) |
| "We examined the effect of a Ca antagonist (nilvadipine) on the occurrence or recurrence of symptomatic stroke in hypertensive patients with MRI-defined asymptomatic cerebral infarction (ACI), periventricular hyperintensity (PVH), and deep and subcortical white matter hyperintensity (DSWMH), with or without a history of stroke, and evaluated the effect of long-term treatment on the lesions." | 5.12 | Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment. ( Fukuuchi, Y; Hirai, S; Okudera, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2007) |
| "To examine the effects of nifedipine GITS on clinical outcome in patients with concurrent stable angina and hypertension." | 5.11 | Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Wagener, G, 2005) |
| "The long-acting calcium antagonist nifedipine reduces the incidence of stroke in Eastern Asia, as shown by the Shanghai Trial Of Nifedipine in the Elderly (STONE) and the Systolic Hypertension in China (Syst-China) trials." | 5.09 | Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke. ( Cornélissen, G; Halberg, F; Kubo, Y; Ohkawa, S; Otsuka, K; Shinagawa, M, 2001) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "Doppler ultrasound and myography were utilised to assess uterine artery functional and structural changes pre-pregnancy and at gestational day 18 in SHRSP (untreated and nifedipine treated) and in the normotensive Wistar-Kyoto (WKY) rat." | 3.83 | Abnormal uterine artery remodelling in the stroke prone spontaneously hypertensive rat. ( Beattie, E; Delles, C; Graham, D; Griffin, S; Indahl, M; Morgan, H; Small, HY, 2016) |
| " This study investigated the effects of nifedipine, an L-type voltage-gated Ca(2+) channel blocker, on ischemic lesion volume after focal cerebral ischemia and reperfusion in rats." | 3.77 | Nifedipine treatment reduces brain damage after transient focal ischemia, possibly through its antioxidative effects. ( Honda, Y; Ide, T; Shiba, T; Tsutsui, H; Yamada, K; Yamato, M, 2011) |
| "Use of short-acting nifedipine was associated with increased risk of stroke occurrence in elderly hypertensive patients." | 3.77 | Short-acting nifedipine and risk of stroke in elderly hypertensive patients. ( Chang, Y; Choi, NK; Jung, SY; Kim, JY; Lee, J; Park, BJ; Song, HJ, 2011) |
| " PAR(2) and bradykinin subtype 2 receptor (B(2)) expression and function were assessed in relation to hypertensive encephalopathy (HE) and cerebral hemorrhage (CH) in middle cerebral arteries (MCA) of Kyoto Wistar stroke-prone spontaneously hypertensive rats (SHRsp)." | 3.76 | Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats. ( Daneshtalab, N; McGuire, JJ; Smeda, JS, 2010) |
| "Nifedipine may inhibit vascular remodeling and improve vascular function by selective activation of PPARgamma through the activation of Cu/ZnSOD in hypertension." | 3.76 | Nifedipine activates PPARgamma and exerts antioxidative action through Cu/ZnSOD independent of blood-pressure lowering in SHRSP. ( Guo, F; Hashimoto, R; Itoh, S; Kishi, H; Kobayashi, S; Matsuzaki, M; Umeji, K; Umemoto, S, 2010) |
| " Benidipine treatment was associated with higher cardiovascular- and cardiac event-free rates than diltiazem treatment, and higher stroke- and ESRD-free rates than nifedipine." | 3.74 | Prognostic effects of calcium channel blockers on cardiac events, stroke and end-stage renal disease in patients with angina pectoris. Retrospective comparative study of benidipine, diltiazem and nifedipine. ( Arioka, I; Dohi, S; Sakai, K, 2008) |
| "026), avoidance of sublingual nifedipine in patients with acute ischemic stroke (97." | 3.73 | Improved quality of stroke care for hospitalized Medicare beneficiaries in Michigan. ( Baker, PL; Jacobs, BS; Levine, SR; Mehta, RH; Roychoudhury, C, 2005) |
| "MCAs from srSHR and prestroke SHRSP exhibited pressure-dependent constriction and constricted in response to vasopressin or serotonin in the presence of nifedipine or the absence of [Ca2+]o." | 3.72 | Stroke development in stroke-prone spontaneously hypertensive rats alters the ability of cerebrovascular muscle to utilize internal Ca2+ to elicit constriction. ( Smeda, JS, 2003) |
| "MCAs from DSS rats after stroke constricted in response to vasopressin but were unable to constrict in response to pressure or PDB in the presence of nifedipine, whereas those from DSS rats before stroke and from DSR rats constricted in response to all the stimuli." | 3.71 | Cerebrovascular alterations in pressure and protein kinase C-mediated constriction in Dahl salt-sensitive rats. ( Payne, GW; Smeda, JS, 2002) |
| "A comparative study of pharmacodynamics and clinical efficacy of nimodipine, nifedipine and foridon in ischemic stroke (late recovery and residual period) was performed in 97 patients with ischemic stroke." | 3.71 | [Comparative clinico-pharmacological characteristics of nimodipine, nifedipine and foridon in the treatment of patients with ischemic stroke in late rehabilitative and residual periods]. ( Kurkova, KS; Svetyĭ, LI, 2002) |
| "Nifedipine and nimodipine, dihydropyridine calcium channel blockers, are commonly used as antihypertensive and antianginal agents in patients at risk for stroke." | 3.70 | Nifedipine and nimodipine competitively inhibit uridine kinase and orotidine-phosphate decarboxylase: theoretical relevance to poor outcome in stroke. ( Najarian, T; Traut, TW, 2000) |
| "Treatments provided to improve dysphagia are aimed at accelerating recovery of swallowing function and reducing these risks." | 2.58 | Swallowing therapy for dysphagia in acute and subacute stroke. ( Bath, PM; Everton, LF; Lee, HS, 2018) |
| "Calcium antagonists are used in the treatment of hypertension and angina." | 2.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| " However, the short-acting formulations of nifedipine had pharmacokinetic properties that were far from ideal and in 1995, several studies involving various dosing regimens reported possible dangerous effects in secondary prevention." | 2.44 | Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension. ( Dunselman, PH; Kragten, JA, 2007) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| " The long-term use of short-acting nifedipine for 30 days was associated with a modest increase in the risk for ischemic stroke (OR 1." | 1.51 | Oral short-acting antihypertensive medications and the occurrence of stroke: a nationwide case-crossover study. ( Chen, PC; Hsu, CY; Huang, LY; Lee, JD; Lee, M; Ovbiagele, B; Saver, JL; Wu, YL, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (57.89) | 29.6817 |
| 2010's | 13 (34.21) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Seto, SL | 1 |
| Barra, ME | 1 |
| Hamidi, A | 1 |
| Sin, JH | 1 |
| Devine, LT | 1 |
| Tauskela, JS | 1 |
| Brunette, E | 1 |
| Aylsworth, A | 1 |
| Zhao, X | 1 |
| Cheng, I | 1 |
| Sasegbon, A | 1 |
| Hamdy, S | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Bath, PM | 1 |
| Lee, HS | 1 |
| Everton, LF | 1 |
| Hsu, CY | 1 |
| Huang, LY | 1 |
| Saver, JL | 1 |
| Wu, YL | 1 |
| Lee, JD | 1 |
| Chen, PC | 1 |
| Lee, M | 1 |
| Ovbiagele, B | 1 |
| Small, HY | 1 |
| Morgan, H | 1 |
| Beattie, E | 1 |
| Griffin, S | 1 |
| Indahl, M | 1 |
| Delles, C | 1 |
| Graham, D | 1 |
| Meredith, PA | 2 |
| Lloyd, SM | 2 |
| Ford, I | 2 |
| Elliott, HL | 2 |
| Hermida, RC | 1 |
| Ayala, DE | 1 |
| Mojón, A | 1 |
| Fernández, JR | 1 |
| Sierra, C | 1 |
| Coca, A | 1 |
| Vokó, Z | 3 |
| Danchin, N | 1 |
| de Brouwer, S | 3 |
| Kirwan, BA | 4 |
| Poole-Wilson, PA | 4 |
| Lubsen, J | 4 |
| Arioka, I | 1 |
| Dohi, S | 2 |
| Sakai, K | 1 |
| Cipolla, MJ | 1 |
| Bullinger, LV | 1 |
| Smeda, JS | 4 |
| McGuire, JJ | 1 |
| Daneshtalab, N | 1 |
| Holzgreve, H | 1 |
| Hashimoto, R | 1 |
| Umemoto, S | 1 |
| Guo, F | 1 |
| Umeji, K | 1 |
| Itoh, S | 1 |
| Kishi, H | 1 |
| Kobayashi, S | 1 |
| Matsuzaki, M | 1 |
| Yamato, M | 1 |
| Shiba, T | 1 |
| Ide, T | 1 |
| Honda, Y | 1 |
| Yamada, K | 1 |
| Tsutsui, H | 1 |
| Jung, SY | 1 |
| Choi, NK | 1 |
| Kim, JY | 1 |
| Chang, Y | 1 |
| Song, HJ | 1 |
| Lee, J | 1 |
| Park, BJ | 1 |
| Buonanno, FS | 1 |
| Spence, JD | 1 |
| Payne, GW | 1 |
| Svetyĭ, LI | 1 |
| Kurkova, KS | 1 |
| White, WB | 1 |
| Altura, BM | 1 |
| Kostellow, AB | 1 |
| Zhang, A | 1 |
| Li, W | 1 |
| Morrill, GA | 1 |
| Gupta, RK | 1 |
| Altura, BT | 1 |
| Wagener, G | 1 |
| Jacobs, BS | 1 |
| Baker, PL | 1 |
| Roychoudhury, C | 1 |
| Mehta, RH | 1 |
| Levine, SR | 1 |
| Clayton, TC | 1 |
| Pocock, SJ | 1 |
| Fox, KA | 1 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Deshpande, LS | 1 |
| Limbrick, DD | 1 |
| Sombati, S | 1 |
| DeLorenzo, RJ | 1 |
| Shinohara, Y | 1 |
| Tohgi, H | 1 |
| Hirai, S | 1 |
| Terashi, A | 1 |
| Fukuuchi, Y | 1 |
| Yamaguchi, T | 1 |
| Okudera, T | 1 |
| Kragten, JA | 1 |
| Dunselman, PH | 1 |
| King, S | 1 |
| Fischberg, GM | 1 |
| Lozano, E | 1 |
| Rajamani, K | 1 |
| Ameriso, S | 1 |
| Fisher, MJ | 1 |
| Najarian, T | 1 |
| Traut, TW | 1 |
| Shinagawa, M | 1 |
| Kubo, Y | 1 |
| Otsuka, K | 1 |
| Ohkawa, S | 1 |
| Cornélissen, G | 1 |
| Halberg, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study[NCT01120613] | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn (stopped due to primary investigator left institution; not enough patients) | |||
| Prognostic Models for People With Stable Coronary Artery Disease[NCT01609465] | 300,000 participants (Anticipated) | Observational | 2010-01-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for nifedipine and Stroke
| Article | Year |
|---|---|
Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis.
Topics: Deglutition; Deglutition Disorders; Humans; Multicenter Studies as Topic; Nifedipine; Stroke | 2022 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Swallowing therapy for dysphagia in acute and subacute stroke.
Topics: Acupuncture Therapy; Acute Disease; Deglutition; Deglutition Disorders; Electric Stimulation Therapy | 2018 |
The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Cor | 2008 |
Clinical trial experience around the globe: focus on calcium-channel blockers.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as To | 2003 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Cost Savings; D | 2007 |
8 trials available for nifedipine and Stroke
| Article | Year |
|---|---|
Importance of sustained and "tight" blood pressure control in patients with high cardiovascular risk.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardio | 2016 |
Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardio | 2016 |
Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rh | 2008 |
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Corona | 2005 |
Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Cohort Studies; Female; Humans; Male; Middle | 2005 |
Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output, Low; Clinical Trials as T | 2007 |
Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Cerebral Infarcti | 2007 |
Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Chronotherapy; Circadian R | 2001 |
23 other studies available for nifedipine and Stroke
| Article | Year |
|---|---|
Efficacy and Safety of Immediate-Release Nifedipine in Critically Ill Patients.
Topics: Antihypertensive Agents; Blood Pressure; Critical Illness; Humans; Hypertension; Hypotension; Nifedi | 2023 |
Neuroprotection against supra-lethal 'stroke in a dish' insults by an anti-excitotoxic receptor antagonist cocktail.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Dizocilpine Maleate; Glucose; Humans; Neuroprotection; Neuropr | 2022 |
Oral short-acting antihypertensive medications and the occurrence of stroke: a nationwide case-crossover study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Captopril; Cerebral Hemorrhage; Female; Humans; La | 2019 |
Abnormal uterine artery remodelling in the stroke prone spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Female; Gestational Age; Hypertension; Nifedipine; | 2016 |
Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: the ACTION experience.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Angiography; Cross-Cultural Comparis | 2010 |
Prognostic effects of calcium channel blockers on cardiac events, stroke and end-stage renal disease in patients with angina pectoris. Retrospective comparative study of benidipine, diltiazem and nifedipine.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Dihydropyridines; Diltiazem; Female; Heart Diseases | 2008 |
Reactivity of brain parenchymal arterioles after ischemia and reperfusion.
Topics: Animals; Arterioles; Brain; Brain Ischemia; Cerebrovascular Circulation; Enzyme Inhibitors; Male; Mi | 2008 |
Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats.
Topics: Animals; Blood Pressure; Bradykinin; Calcium Channel Blockers; Cyclooxygenase Inhibitors; Cytochrome | 2010 |
[Hypertensive urgency or hypertensive emergency?].
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Emergencies; Female; Follow-Up Studies | 2010 |
Nifedipine activates PPARgamma and exerts antioxidative action through Cu/ZnSOD independent of blood-pressure lowering in SHRSP.
Topics: Anilides; Animals; Aorta; Blood Pressure; Calcium Channel Blockers; Cells, Cultured; Endothelium, Va | 2010 |
Nifedipine treatment reduces brain damage after transient focal ischemia, possibly through its antioxidative effects.
Topics: Animals; Antioxidants; Brain; Brain Ischemia; Male; Mitochondria; Nifedipine; Oxidative Stress; Rats | 2011 |
Short-acting nifedipine and risk of stroke in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Confidence Intervals; Cross-Over Studies; Female; Hospitalization; Humans; | 2011 |
Short-acting nifedipine and risk of stroke.
Topics: Female; Humans; Male; Nifedipine; Stroke; Vasodilator Agents | 2011 |
Cerebrovascular alterations in pressure and protein kinase C-mediated constriction in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Disease Models, Animal | 2002 |
[Comparative clinico-pharmacological characteristics of nimodipine, nifedipine and foridon in the treatment of patients with ischemic stroke in late rehabilitative and residual periods].
Topics: Calcium Channel Blockers; Cerebrovascular Circulation; Female; Follow-Up Studies; Hemodynamics; Huma | 2002 |
Stroke development in stroke-prone spontaneously hypertensive rats alters the ability of cerebrovascular muscle to utilize internal Ca2+ to elicit constriction.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models | 2003 |
Expression of the nuclear factor-kappaB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis, and stroke.
Topics: Animals; Aorta, Thoracic; Biomarkers; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Di | 2003 |
Improved quality of stroke care for hospitalized Medicare beneficiaries in Michigan.
Topics: Administration, Sublingual; Aged; Aged, 80 and over; Fee-for-Service Plans; Female; Hospitalization; | 2005 |
Activation of a novel injury-induced calcium-permeable channel that plays a key role in causing extended neuronal depolarization and initiating neuronal death in excitotoxic neuronal injury.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Animals, Newborn; Apoptosis; Calcium; Calcium Channel | 2007 |
Electromechanical alterations in the cerebrovasculature of stroke-prone rats.
Topics: Animals; Calcium; Calcium Channel Blockers; Cerebral Arteries; Electrophysiology; Genetic Predisposi | 2000 |
Stroke precipitated by moderate blood pressure reduction.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Emergency Treatment; Felodipine; Female; Humans; Hyp | 2000 |
Nifedipine and nimodipine competitively inhibit uridine kinase and orotidine-phosphate decarboxylase: theoretical relevance to poor outcome in stroke.
Topics: Animals; Binding, Competitive; Brain; Calcium Channel Blockers; Cell Membrane; Humans; Neurons; Nife | 2000 |
Did nurses fail to 'give Procardia' as ordered? Case on point: Piro v. Chandler, 2000 WL 1634167 So.2d--LA.
Topics: Humans; Hypertension; Male; Malpractice; New Jersey; Nifedipine; Nursing Staff, Hospital; Stroke; Va | 2000 |